As European markets navigate a complex landscape of stalled geopolitical negotiations and fluctuating oil prices, the pan-European STOXX Europe 600 Index has remained largely stable with slight positive momentum in corporate earnings. In this environment, stocks with high insider ownership can be particularly attractive to investors seeking growth opportunities, as they often indicate strong alignment between company leadership and shareholders’ interests.
Top 10 Growth Companies With High Insider Ownership In Europe
Name
Insider Ownership
Earnings Growth
Newron Pharmaceuticals (SWX:NWRN)
10.5%
50.2%
KebNi (OM:KEBNI B)
11.8%
82.7%
Hacksaw (OM:HACK)
13.2%
24.8%
Envipco Holding (ENXTAM:ENVI)
19.5%
46.5%
Elliptic Laboratories (OB:ELABS)
19.8%
124.9%
CTT Systems (OM:CTT)
17.4%
47.1%
Clavister Holding AB (publ.) (OM:CLAV)
18%
81.8%
Circus (XTRA:CA1)
21.9%
88%
Bonesupport Holding (OM:BONEX)
10.3%
34.5%
Bergen Carbon Solutions (OB:BCS)
11.9%
55.5%
We’re going to check out a few of the best picks from our screener tool.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Framery Group Oyj designs, manufactures, and markets soundproof private workspaces and related software solutions to address noise and privacy issues in open offices across Europe, the Middle East, Africa, the Americas, and Asia Pacific with a market cap of €543.67 million.
Operations: Revenue segments for Framery Group Oyj include the design, manufacture, and marketing of soundproof private workspaces and related software solutions and pods across Europe, the Middle East, Africa, the Americas, and Asia Pacific.
Insider Ownership: 15.6%
Earnings Growth Forecast: 24% p.a.
Framery Group Oyj, a growth-focused company with substantial insider ownership, is set to expand its manufacturing operations to the United States. This strategic move supports its growth strategy by optimizing supply chains and meeting local demand. While revenue growth is slower than 20% annually, earnings are forecasted to grow significantly at 24% per year. Insider activity shows more buying than selling recently, indicating confidence in the company’s future prospects despite high volatility and debt levels.
HLSE:FRAMERY Earnings and Revenue Growth as at May 2026
Simply Wall St Growth Rating: ★★★★☆☆
Overview: ITAB Shop Concept AB (publ) specializes in developing, manufacturing, selling, and installing store concepts for retail chain stores, with a market cap of approximately SEK3.48 billion.
Operations: ITAB Shop Concept AB’s revenue segments focus on the development, manufacturing, sales, and installation of store concepts tailored for retail chain stores.
Insider Ownership: 25.4%
Earnings Growth Forecast: 42.1% p.a.
ITAB Shop Concept demonstrates strong growth potential with earnings forecasted to grow significantly at 42.1% annually, outpacing the Swedish market. Recent insider activity shows more buying than selling, reflecting confidence in its future prospects. The company reported improved Q1 2026 earnings with net income rising to SEK 65 million from SEK 37 million a year ago. A new EUR 12 million agreement with a UK grocery chain further supports ITAB’s strategic expansion and revenue growth initiatives.
OM:ITAB Earnings and Revenue Growth as at May 2026
Simply Wall St Growth Rating: ★★★★★☆
Overview: Formycon AG is a biotechnology company focused on developing biosimilar drugs in Germany and Switzerland, with a market cap of €317.05 million.
Operations: Revenue Segments (in millions of €): The company generates revenue through the development and commercialization of biosimilar drugs in Germany and Switzerland.
Insider Ownership: 14.2%
Earnings Growth Forecast: 111.5% p.a.
Formycon AG shows promising growth potential with its revenue forecasted to increase by 36% annually, surpassing the German market average. Despite a net loss of €64.7 million in 2025, the company expects revenues between €60 million and €70 million for 2026. Insider ownership remains significant, aligning with Formycon’s strategic focus on biosimilars like FYB206, which recently achieved key clinical milestones and secured an exclusive licensing agreement in Asia-Pacific.
XTRA:FYB Earnings and Revenue Growth as at May 2026 Next Steps
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include HLSE:FRAMERY OM:ITAB and XTRA:FYB.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com